Altogether, our results demonstrate functional heterogeneity in MET pathway activation upon osimertinib resistance in EGFR-mutant NSCLC, which may help guide the use of osimertinib and savolitinib combination in the clinic. This evidence concerns the gene MET and non-small cell lung carcinoma.